Summit Therapeutics Inc. Class of Warrant or Right, Outstanding
Summit Therapeutics Inc. (SMMT) had Class of Warrant or Right, Outstanding of 0 shares as of 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Notes
us-gaap:ClassOfWarrantOrRightOutstanding · last filed 2026-07-23
- 2026-06-30: Class of Warrant or Right, Outstanding 0.00 shares.
- 2026-03-31: Class of Warrant or Right, Outstanding 0.00 shares.
- 2025-12-31: Class of Warrant or Right, Outstanding 0.00 shares.
- 2025-09-30: Class of Warrant or Right, Outstanding 0.00 shares.
| Period end | Class of Warrant or Right, Outstanding |
|---|---|
| 2026-06-30 | 0.00 shares 10-Q · filed 2026-07-23 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-04-30 |
| 2025-12-31 | 0.00 shares 10-Q · filed 2026-07-23 |
| 2025-09-30 | 0.00 shares 10-Q · filed 2025-10-20 |
| 2025-06-30 | 0.00 shares 10-Q · filed 2025-08-11 |
| 2025-03-31 | 1.05M shares 10-Q · filed 2025-05-01 |
| 2024-12-31 | 4.63M shares 10-K · filed 2026-02-23 |
| 2024-09-30 | 4.95M shares 10-Q · filed 2024-10-30 |
| 2024-06-30 | 4.95M shares 10-Q · filed 2024-08-06 |
| 2024-03-31 | 5.02M shares 10-Q · filed 2024-05-01 |
| 2023-12-31 | 5.02M shares 10-K · filed 2025-02-24 |
| 2022-12-31 | 5.82M shares 10-K · filed 2024-02-20 |
| 2021-12-31 | 5.82M shares 10-K · filed 2023-03-09 |
| 2020-12-31 | 5.82M shares 10-K/A · filed 2022-12-21 |
| 2019-12-31 | 8.62M shares 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |